Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 13, 2007Journal of Clinical OncologyOpen Access

Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChristine I. ChenPrincess Margaret Cancer CentreCKC. Tom KouroukisJuravinski Cancer CentreDWDarrell WhiteDalhousie University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chen et al. (2007) studied this question.

synapsesocial.com/papers/6a81a3b021d82b3fa6775f0bhttps://doi.org/10.1200/jco.2006.07.8659
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Idarubicin in the Initial Treatment of Adults with Acute Lymphoblastic Leukemia: The Effect of Drug Schedule on Outcome1993 · 21 citations
  2. 2Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.1994 · 129 citations
  3. 3Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies2002 · 767 citations
  4. 4Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas1999 · 3,494 citations
  5. 5CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia2001 · 149 citations